Renaissance Capital logo

Dyne Therapeutics Priced, Nasdaq: DYN

Preclinical biotech developing oligonucleotide therapies for rare muscular diseases.

Industry: Health Care

Latest Trade: $22.00 0.00 (0.0%)

First Day Return: +25.8%

Return from IPO: +15.8%

Industry: Health Care

We are building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. We are utilizing our proprietary FORCE platform to overcome the current limitations of muscle tissue delivery and advance modern oligonucleotide therapeutics for muscle diseases. With our FORCE platform, we have the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using our FORCE platform, we are assembling a broad portfolio of muscle disease therapeutics, including our lead programs in myotonic dystrophy type 1, or DM1, Duchenne muscular dystrophy, or DMD, and facioscapulohumeral dystrophy, or FSHD. In addition, we plan to expand our portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases, including some with larger patient populations. Our programs are currently all in the preclinical stage. We expect to submit investigational new drug, or IND, applications to the U.S. Food and Drug Administration, or FDA, for product candidates in each of our DM1, DMD and FSHD programs between the fourth quarter of 2021 and the fourth quarter of 2022.
more less
IPO News for Dyne Therapeutics
more
IPO Data
IPO File Date 08/25/2020
Offer Price $19.00
Price Range $16.00 - $18.00
Offer Shares (mm) 12.3
Deal Size ($mm) $233
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/16/2020
Offer Price $19.00
Price Range $16.00 - $18.00
Offer Shares (mm) 12.3
Deal Size ($mm) $233
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Waltham, MA
Founded 2017
Employees 37
Website www.dyne-tx.com